Group 1 - The medical beauty industry is expected to maintain robust growth in the high single digits over the next three years, with significant structural opportunities within the sector [1] - Certain medical beauty materials still present track dividends, such as natural and recombinant collagen, as well as regenerative microspheres, and materials like PDRN, ECM, silk protein, and PHA that have yet to see the first certification [1] - Companies with platform capabilities in upstream product development and downstream medical beauty institutions that possess high reputation, integrate upstream resources, and maintain differentiation through comprehensive solutions are highlighted as key players [1]